Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + venlafaxine + lithium
- Development stage
- Preclinical
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of three psychiatric medications used for treatment-resistant depression. Escitalopram is a selective serotonin reuptake inhibitor (SSRI), venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI), and lithium is a mood stabilizer. This combination is not a single formulated product but rather a therapeutic approach that may be used in cases where monotherapy has failed. The combination carries an increased risk of serotonin syndrome due to the enhanced serotonergic effects of all three agents.
02
Targets
NET (Norepinephrine Transporter)TPH1 (Tryptophan 5-hydroxylase 1)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on escitalopram + venlafaxine + lithium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + venlafaxine + lithium.